The increase in price target from $25 to $45 by Mizuho reflects a positive outlook on Cerevel Therapeutics Hldg's future performance, potentially leading to increased investor interest and a positive short-term impact on the stock price. The Neutral rating suggests that while the analyst sees improved prospects, there may still be factors that could limit the stock's upward movement in the short term.